To hear about similar clinical trials, please enter your email below
Trial Title:
Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
NCT ID:
NCT05925751
Condition:
Non-small Cell Lung Cancer
Neoadjuvant Chemoimmunotherapy
Complete Pathological Response
Conditions: Official terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Pathologic Complete Response
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
CT/PET/WSI-based Deep Learning Signature
Description:
CT/PET/WSI-based Deep Learning Signature for Predicting Complete Pathological Response to
Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer
Summary:
The purpose of this study is to evaluate the performance of a CT/PET/ WSI-based deep
learning signature for predicting complete pathological response to neoadjuvant
chemoimmunotherapy in non-small cell lung cancer
Criteria for eligibility:
Study pop:
Resected Stage I-III NSCLC following neoadjuvant chemoimmunotherapy
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Age ranging from 20-75 years;
2. Patients who underwent curative surgery after neoadjuvant chemoimmunotherapy for
NSCLC;
3. Obtained written informed consent.
Exclusion Criteria:
1. Missing image data;
2. Pathological N3 disease.
Gender:
All
Minimum age:
20 Years
Maximum age:
75 Years
Locations:
Facility:
Name:
Affiliated Hospital of Zunyi Medical University
Address:
City:
Zunyi
Country:
China
Status:
Recruiting
Contact:
Last name:
Yongxiang Song, Dr
Phone:
15505177258
Email:
zhong961008@163.com
Facility:
Name:
The First Affiliated Hospital of Nanchang University
Address:
City:
Nanchang
Country:
China
Status:
Recruiting
Contact:
Last name:
Bentong Yu, Dr
Phone:
021-65115006
Email:
1151697503@qq.com
Facility:
Name:
Ningbo HwaMei Hospital
Address:
City:
Ningbo
Country:
China
Status:
Recruiting
Contact:
Last name:
Minglei Yang, Dr
Phone:
021-65115006
Email:
almondjj@163.com
Start date:
May 1, 2023
Completion date:
October 31, 2023
Lead sponsor:
Agency:
Shanghai Pulmonary Hospital, Shanghai, China
Agency class:
Other
Collaborator:
Agency:
Ningbo No.2 Hospital
Agency class:
Other
Collaborator:
Agency:
Zunyi Medical College
Agency class:
Other
Collaborator:
Agency:
The First Affiliated Hospital of Nanchang University
Agency class:
Other
Source:
Shanghai Pulmonary Hospital, Shanghai, China
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05925751
